Last reviewed · How we verify

NCT04501367

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Status unknown Phase 4 Last updated 29 June 2023
What this trial tests

Phase 4 trial testing Dexamethasone Intracanalicular Insert, 0.4 mg in Vitrectomy in 60 participants. Status unknown.

Timeline
27 April 2021
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorKovach Eye Institute
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date27 April 2021
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Kovach Eye Institute

Who can join

18 and older, any sex, with Vitrectomy or Macular Pucker. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Kovach Eye Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04501367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing